Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Mepolizumab Panel Review May Hinge On Eosinophil Utility In Patient Selection

This article was originally published in The Pink Sheet Daily

Executive Summary

With a high regulatory bar for safety and efficacy for new asthma drugs and a skeptical payer base, the significance of and effect on eosinophil counts will be a crucial consideration for the severe asthma candidate.

You may also be interested in...



FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel

Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.

On The Respiratory Horizon: A Wave Of Biologics For Asthma

Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.

Payment Schemes For Innovative Medtech Exist In Just 8 European Countries - Report

Innovative medtech products should receive reimbursement based on the value they add to the health care system, but just eight European countries offer funding pathways at present, analysis by MedTech Europe and Med Tech Reimbursement Consulting shows.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel